{"title":"生物标志物的追求:在血液学/肿瘤学中保持最新的生物标志物。","authors":"Beth Faiman, Sandra E Kurtin, Rasheda Persinger","doi":"10.6004/jadpro.2023.14.3.8","DOIUrl":null,"url":null,"abstract":"<p><p>In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and reviewed recommendations and guidelines for biomarker testing.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"223-226"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/83/jadpro-14-223.PMC10184845.pdf","citationCount":"0","resultStr":"{\"title\":\"Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology.\",\"authors\":\"Beth Faiman, Sandra E Kurtin, Rasheda Persinger\",\"doi\":\"10.6004/jadpro.2023.14.3.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and reviewed recommendations and guidelines for biomarker testing.</p>\",\"PeriodicalId\":17176,\"journal\":{\"name\":\"Journal of the Advanced Practitioner in Oncology\",\"volume\":\"14 3\",\"pages\":\"223-226\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/83/jadpro-14-223.PMC10184845.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Advanced Practitioner in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.3.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.3.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在JADPRO Live 2022上流行的以生物标志物为重点的会议上，演讲者将生物标志物与肿瘤类型配对，这些肿瘤类型的表达最常用于确定靶向治疗，确定了用于测量常见生物标志物的关键检测方法，并回顾了生物标志物检测的建议和指南。
Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology.
In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and reviewed recommendations and guidelines for biomarker testing.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
